Skin Cancer | Topics

 
Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC
September 12, 2022

Neoadjuvant treatment with cemiplimab led to near or complete disappearance of cutaneous squamous cell carcinoma in almost 64% of patients set to undergo surgery.

RP1/Nivolumab Yields Promising Antitumor Activity in Non-Melanoma Skin Cancer
February 26, 2022

Patients with non-melanoma skin cancer achieved promising antitumor activity following treatment with RP1 and nivolumab.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma
February 14, 2022

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.

Cosibelimab Achieves Promising Responses in Metastatic Cutaneous Squamous Cell Carcinoma
February 02, 2022

Patients with metastatic cutaneous squamous cell carcinoma who were treated with cosibelimab experienced a positive objective response rate.

The complexity of carcinosarcoma
December 21, 2021

Sunil A. Reddy, MD gives his perspective on the article, Metastatic Basal Cell (BCC) Arising from a Primary Cutaneous Carcinosarcoma.

Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma
December 20, 2021

This study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.

Duration of Treatment for Melanoma
November 02, 2021

John Kirkwood, MD, PhD, gives his opinion on duration of treatment for patients with melanoma.

Taking Drug Holidays Amidst Melanoma Therapy
November 02, 2021

Dr John Kirkwood explores the idea of taking drug holidays during melanoma treatment and whether it is helpful or harmful.

How the Emergence of Immunotherapy has Impacted Practice Patterns for Treatment and Management of Merkel Cell Carcinoma
October 19, 2021

A retrospective review identified that clinical practice patterns have changed from 2002 to 2020, with the use of immunotherapy increasing as chemotherapy and radiation therapy use has decreased for patients with Merkel cell carcinoma.

Cemiplimab Shows Clinical Benefit for BCC After Hedgehog Inhibitor Therapy
July 31, 2021

Cemiplimab for patients with either metastatic or locally advanced basal cell carcinoma showed antitumor activity in a phase 2 trial.